Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linagliptin and metformin when administered singularly.

Key facts

Study ID

NCT01845077

Run by

Boehringer Ingelheim

People needed

72

Starts

2013-05-01

Expected to finish

2013-08-01

Last updated by the study team

2014-08-19

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females
• Age 18 -50 years (incl)
• Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
• Subjects must be able to understand and comply with study requirements

You may not qualify if…

• Any deviation from healthy condition

Where it is running

• 1288.8.1 Boehringer Ingelheim Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.